INM InMed Pharmaceuticals Inc.
Healthcare$1.72+0.00%ClosedMarket Cap: $3.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.01
P/S
0.00
EV/EBITDA
0.17
DCF Value
$-14.58
FCF Yield
-289.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.2%
Operating Margin
-1.5%
Net Margin
-1.5%
ROE
-72.7%
ROA
-108.5%
ROIC
-135.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $659.8M | -0.0% | $-2.8M | $-3.0M | $— | — |
| Q2 null | $1.1M | 3.2% | $-2.9M | $-2.8M | $— | — |
| Q1 null | $1.1M | 36.0% | $-1.8M | $-1.7M | $— | — |
| Q4 null | $1.8M | 44.2% | $-2.4M | $-2.4M | $— | — |
| FY null | $4.9M | 34.5% | $-7.9M | $-8.2M | $— | — |
| Q3 null | $1.3M | 13.9% | $-2.1M | $-2.1M | $— | — |
| Q2 null | $1.1M | 41.5% | $-2.2M | $-2.6M | $— | — |
| Q1 null | $1.3M | 39.0% | $-1.8M | $-1.7M | $— | — |
| Q4 null | $1.3M | 36.3% | $-2.0M | $-1.9M | $— | — |
| FY null | $4.6M | 23.9% | $-8.1M | $-7.7M | $— | — |
| Q3 null | $1.2M | 24.7% | $-1.8M | $-1.7M | $— | — |
| Q2 2024 | $1.2M | 26.1% | $-1.7M | $-1.5M | $-3.71 | — |